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DexmedetomidineAbstract PRES, a reversible white matter lesion characterized by cerebral edema, found in 7–20%
of the patients with preeclampsia and eclampsia, needs early diagnosis and therapeutic intervention.
We report PRES in a young preeclamptic primigravida and the role of dexmedetomidine in control-
ling her uncontrollable blood pressure in ICU. Dexmedetomidine, has cerebroprotective cardiopro-
tective and renoprotective properties all of which, helped the patient improving clinically.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
PRES is a multifactorial cliniconeuroradiological syndrome
characterized by headache, confusion, seizures, sometimes cor-
tical visual disturbances, predominantly affecting the posterior
circulation of the brain [1]. The prompt control of blood pres-
sure or discontinuation of the offending medication leads to
the reversal of the clinical and radiologic abnormalities. When
unrecognized, irreversible cytotoxic edema may occur [2].
Here, we report PRES in a young preeclamptic primi-
gravida and the role of dexmedetomidine in controlling her
uncontrollable blood pressure in ICU.
A 23 yrs postpartum patient was referred from Khanpur
community health center to emergency department of PGIMS,
Rohtak, as she became drowsy with poor mentation followingnormal preterm delivery of a IUGR baby. Antepartum history
revealed that she was a known preeclamptic primigravida on
regular antihypertensive medications and her premature induc-
tion of labor was done on 36th gestational week in view of
uncontrollable high blood pressure (160/96 mmHg). She had
no history of fits and her both past and family history was non-
contributory. On examination in the emergency department
patient was irritable with no response to any verbal com-
mands. Vitals recorded were BP 140/90 mmHg, PR 96/min,
Spo2 96% (on room air), normothermic, Resp. rate of 16/
min, bilateral vesicular breath sounds audible with normal
heart sounds. On pervaginal examination there was no fresh
blood loss. All routine investigations were sent and ringer lac-
tate drip was started. NCCT head was done. As the patient
remained drowsy it was decided to shift the patient to ICU
for close monitoring. Vitals recorded in the ICU were GCS
8/15 (E1 V2 M5), pt. was breathing spontaneously with resp.
rate of 15/min, HR 76/min, BP 146/100 mmHg maintaining
a Spo2 of 95% on Fio2 0.4 on ventimask. NCCT head
revealed hypodensity in bilateral occipital region with no mid-
line shift and intra cranial bleed which are the typical CT scan
findings seen in Postpartum Reversible Encephalopathy Syn-
drome (PRES). Preemptive neuroprotective medications were.doi.org/
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Figure 1 PRES: Blood Pressure Variation with various therapeutic interventions.
2 G. Ahlawat et al.started with Inj. Mannitol 100cc IV tds, Inj. Dexamethasone
8 mg IV tds and Inj Phenytoin 150 mg IV tds. Inj. Labetalol
10 mg IV tds and Inj Lasix 20 mg IV tds were also started.
Routine investigations revealed Hb 9.9 gm/dl, TLC 29,000,
DLC 88/10/1/1 platelets 1 lac, blood urea 94 mg/dl, blood
sugar 96 mg/dl, serum sodium and potassium were 143 and
4.6 Meq/L respectively. Arterial blood gas revealed pH 7.42,
Pco2 26.4, HCO3 16, Spo2 99.4%, SGOT/PT 51/69 IU/L,
Serum ALP 384 IU/L, Serum Protein 5.5 gm/dl, A/G ratio
0.6, and Serum Cr 1.1 mg/dl. NIBP was regularly monitored
and the BP remained high for the next 2 days with average
BP at 184/96 mmHg. After physician opinion Tab Telmisartan
40 mg and Tab Amlodipine 10 mg were started on the 3rd
postpartum day. Duplex scan done on both lower limbs ruled
out chances of DVT. For the first 3 days patients remained agi-
tated and were delirious with very high blood pressure.
Dexmedetomidine infusion was added (3–7 lg/kg) to sedate
as well to control the blood pressure. From 4th post partum
day she showed signs of improvement in mentation and the
average blood pressure remained at 150/94 mmHg. All intra-
venous medications were gradually stopped but Tab Telmisar-
tan 40 mg and Tab Amlodipine 10 mg were continued. On 5th
day patient was conscious with blood pressure at
140/86 mmHg (Fig. 1). Patient was shifted to ward and on
6th postpartum day she was discharged from hospital.
2. Discussion
PRES is mainly characterized by reversible white matter
lesions; however, irreversible ischemic injury may occur due
to delay in intervention. Though the exact etiopathogenesis
remains unclear, it has been hypothesized that the cause of
widespread endothelial dysfunction is due to sepsis, toxic
agents or release of immunological mediators [3]. In hyperten-
sive patient rapid rise of blood pressure with abnormal cere-
bral autoregulation breaks the blood brain barrier and leads
to cerebral edema in the posterior areas of the brain [4]. When
unrecognized, irreversible cytotoxic edema, infarction, hemor-
rhage and coma may occur. Clinical findings can mimic condi-
tions such as stroke and vasculitis, as well as they are typicallyPlease cite this article in press as: Ahlawat G et al. Dexmedetomidine in PRES: A
10.1016/j.egja.2016.08.006indistinguishable among cases of PRES, regardless of the
underlying cause and hence can be misdiagnosed. Neuroimag-
ing findings are diagnostic. It is mainly diagnosed by reversible
hyperintensities on T2-weighted cranial MRI or bilateral sym-
metrical areas of low attenuation of white matter on CT scan
which provides prognostic information that guides therapeutic
decisions [5]. Recognizing characteristic image findings is the
key to diagnosing this syndrome and preventing deleterious
workups or therapies. 7–20% of the patients with preeclampsia
and eclampsia have PRES, as they are prone to excess fluid
accumulation due to altered vascular reactivity, deficiency of
vasodilating prostaglandins and endothelial dysfunction. Man-
agement of PRES mainly includes treatment of the underlying
cause and maintaining normotension. Antiepileptics, antihy-
pertensives and steroids (to reduce cerebral edema) are used
to control PRES [6].
Dexmedetomidine is a highly selective a2-adrenoreceptor
agonist that produces dose-dependent sedation, anxiolysis,
and analgesia (involving spinal and supraspinal sites) without
respiratory depression making it a potentially attractive seda-
tive for neurocritical care patients [7]. Although a2-
adrenoreceptors are located throughout the body, they are pre-
sent in larger concentrations in vascular smooth muscle and in
key arousal areas of the central nervous system (CNS), such as
the locus coeruleus. The stimulation of a-2 receptors in the
brain and spinal cord inhibits neuronal firing, which leads to
hypotension, bradycardia, sedation and analgesia [8]. Activa-
tion of presynaptic a2-adrenoreceptor on cortical blood vessels
decreases norepinephrine release, whereas postsynaptic a2-
adrenoreceptors may directly increase vascular smooth muscle
tone so, rapid infusion or loading dose of dexmedetomidine
may cause initial transient hypertension and it should be
avoided [8,9]. It mainly decreases norepinephrine release by
equally acting on a2A, a2B and a2C receptor subtypes [10].
In our case the patient had postpartum neurological symp-
toms of headache, irritability and confusion with no history of
seizures or visual disturbances. The BP recorded in the emer-
gency department was 142/90 mmHg. Eventually she was diag-
nosed as PRES on CT scan. MRI was not done, as CT scan
clearly showed hypodensity in the bilateral occipital regionn appropriate therapeutic decision, Egypt J Anaesth (2016), http://dx.doi.org/
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tors causing PRES in this period. Recognizing the need for
early therapeutic intervention to control blood pressure,
patient was shifted to ICU for close monitoring of all vital
parameters. She experienced a surge in blood pressure for
the initial 2 days which was not controlled by intravenous labe-
talol, lasix, mannitol and NTG. On 3rd day tab. amlodipine
was started with mild decrease in blood pressure. Then, it
was decided to start infusion of dexmedetomidine (2–7 lg/dl)
which controlled the blood pressure and also helped to
improve the delirious state of the patient. Giving rapid infu-
sion would have lead to further increase in blood pressure
and hence it was avoided. It has cerebroprotective cardiopro-
tective and renoprotective properties all of which improved
our patient clinically.
Diagnosing PRES has important therapeutic implications
because of its potential reversibility. Dexmedetomidine could
be a rescue therapy for PRES, as it not only improves the
hemodynamic parameters of the patient but also, has a known
cerebroprotective as well as renoprotective effect, hence bene-
ficial for two vital organs most affected by PRES. Dexmedeto-
midine could thus be considered as a treatment modality in
patients with PRES, though more research in this field is
warranted.
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